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1. Introduction  
Available data from literature show that among patients suffering from serious mental 
illnesses it was observed that about 50% of them abused psychoactive substances during 
their lives (Kessler et al., 1996). And the dependence on such substances like cannabis, 
amphetamine, or cocaine is more common in patients suffering from schizophrenia than in 
other psychiatric patients (May-Majewski, 2002). It was found that in the North American 
population every fourth person suffering from schizophrenia abused alcohol (Helzer & 
Pryzbeck, 1998). The objective of this study is to analyze data from literature concerning the 
reasons for psychoactive substance abuse by persons suffering from psychiatric disorders 
and to discuss the most effective treatment strategies for them. A very important part of this 
analysis is the so called self-treatment hypothesis formulated by Khantzian (1985). Its 
definition embraces two elements. Firstly ill persons use psychoactive substances, because 
they decrease their psychological discomfort. On the other hand there is a great degree in 
psychopharmacological specificity in choosing the abused substance.  
2. Definition of dual diagnosis 
In the diagnostic process in psychiatry it often happens to set two or more diagnoses in the 
same patient. "Dual diagnosis" is a concept that doesn't appear in the official nomenclature 
of mental health and is not included in the ICD-10 and DSM-IV classifications. In a very 
general sense it concerns a patient who presents a psychopathological picture, in which we 
find simultaneously fulfilled criteria for two different psychiatric disorders. However, in 
recent years, the term "dual diagnosis" has become synonymous with the coexistence of 
psychiatric disorders and psychoactive substance dependence (Solomon et al., 1993) and this 
coexistence can consist of the following options: 
1. Mental illness and drug dependence. 
2. Drug dependence and personality disorders. 
3. Acute psychotic disorders resulting from substance use. 
4. Drug dependence, mental illness and organic disorders in different combinations 
(Sciacca, 1987). 
Patients with a dual diagnosis can cause many problems in the diagnostic process and 
therapy at different stages of treatment both in the psychiatric and in the addiction 
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treatment systems. One of the most common examples of a dual diagnosis encountered in 
psychiatric clinical practice is comorbodity of schizophrenia or bipolar disorder and 
psychoactive substance dependence.  
3. Epidemiology and demographics of dual diagnosis 
In recent years, there has been a gradually growing awareness that the problems associated 
with abuse and addiction to psychoactive substances are very common in people with 
various mental disorders, including schizophrenia and bipolar disorder. But, although there 
is an increasing number of reports from the literature that these coexisting disorders are 
very common, as yet few therapeutic programs based on empirical data targeted specifically 
at this group of patients have been developed (Lewin & Hennesy, 1994). Based on available 
evidence, we can try to desribe the scale of the problem. The incidence of bipolar disorder 
and coexisting abuse of psychoactive substances has been described inter alia in the 
Epidemiological Catchment Area Study (Regier et al, 1990). This study was conducted 
among participants from five different municipalities in the U.S.. It showed that, in 
comparison with with patients with other psychiatric disorders, people with bipolar 
disorder had the highest comorbidity of disorders associated with alcohol use (46%) and 
drugs (41%). In addition, rates of disorders associated with the use of alcohol and drugs in 
people with bipolar disorder were much higher than the associated disorders in the general 
population (14% and 6%). It was also observed that in bipolar I there was a higher risk of co-
existence of problems associated with substance abuse in comparison with bipolar II, wich 
were respectively 61% and 48% (Lewin & Hennesy, 1994). These results were confirmed by 
further epidemiological studies. In the National Comorbidity Study (NCS) focused on the 
respondents with a lifetime alcohol or drug use disorder, recruited for the evaluation, it was 
found that 51,4% of them also met criteria for at least one lifetime mental disorder. 50.9% of 
the NCS respondents with a lifetime mental disorder also had a history of alcohol or drug 
abuse or dependence (Kessler et al., 1996). As mentioned above, one of the most common 
example of dual diagnosic in the coexistence of schizophrenia and addiction to substances. 
In the studies of Helzer and Pryzbeck (1998) it was found out that four times more alcoholic 
than non-alcoholic subjects suffer from schizophrenia. The abuse of stimulants four times 
more common in schizophrenic than non-schizophrenic subjects (Leduc & Mittleman, 1995). 
In New York State among each 100 patients hospitalised for their first episode of 
schizophrenia, 35% of them were addicted to illicit drugs. During the relapses of 
schizophrenia 22% of the patients use psychoactive substances (DeLisi et al., 1991). 
3.1 Young age of patients with dual diagnosis 
Patients with dual diagnosis are often young people. De Millo (1989) observed the 
prevalence of various psychiatric disorders among adolescents addicted to drugs, which 
was much higher that a paralell incidence among adults, but he also emphasises the fact that 
there is a lack of standardisation of diagnostic tools for this population. According to 
Lysaker et al. (1994) among schizophrenic patients with concomitant use of cocaine, the age 
of first hospitalisation was earlier than in patients not biased. In turn, according to Menezes 
(1996) patients with dual diagnosis are mainly young men. These observations confirm the 
evaluations from the studies of Maynard and Cox (1998), who compared the demographic 
structure of patients hospitalised in psychiatric hospitals in the United States. They showed 
that among patients with dual diagnosis there was a larger number of younger ones 
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(average age of 36-37 years), compared with those which had only a single psychiatric 
diagnosis (mean age of 42-43 years).  
A study done in Swiss population, which was conducted in different groups of 
schizophrenic patients presented a higher average age of subjects without addiction, and 
also of those who were solely dependent on alcohol, in comparison with patients with a 
history of illicit drug abuse (Modestin et al., 2001).  
Similarly, Kavanagh et al. (2004), examining patients with dual diagnosis in the population 
of Australia, found that the incidence of alcohol use in patients with dual diagnosis did not 
depend on the age group, whereas the use of other psychoactive substances was higher in 
younger groups. Epidemiological studies in England showed that the average age of 
patients with dual diagnosis is within the range of 34-38 years, but recent trends show a 
gradual decline of this age (Frisher et al., 2004).  
3.2 Sex differences among dual diagnosis patients 
When discussing issues related to the comorbidity of a seriuos maental disorder and 
addiction to psychoactive substances, an important factor to be considered is the sex. 
Lewine (1981) in his review of the literature devoted to the differences between men and 
women suffering from schizophrenia emphasises that men are characterized by poorer 
premorbid social functioning, earlier age of first hospitalisation, more severe negative 
symptoms, more severe disease. Better premorbid functioning of women with schizophrenia 
is an element often emphasised in the literature. Women at the time of onset have a better 
social contacts, higher education, more permanent job, most of them have already left home, 
got married, or have a regular partner (Kalisz et al., 2001). Girls more often than boys have a 
secondary education (Krupka-Matuszczyk, 1998). Research on gender differences in 
schizophrenia have shown that women experience a milder form of the disease than men, 
which is associated with better premorbid functioning. Gearon and Bellack (2000) draw 
attention to the gender difference in patients with dual diagnosis. In the group of 
outpatients with coexisting schizophrenia and psychoactive substance dependence found 
that women, despite a better premorbid functioning and later age of onset, experience a 
deterioration, when they begin to use drugs. This may indicate that women are particularly 
susceptible to the adverse effects of psychoactive substances. The use of these substances 
and related social deficits, and reduced ability to process information in them may impair 
the ability to recognise hazards, such as the threat of violence or rape and protect 
themselves against them (Bellack & Gearon, 1998). Prevalence of drug use also has a 
correlation with gender. As noted Sieroslawski, in studies conducted in Poland and Europe 
in the early 90's, the prevalence among boys was more than twice higher than in girls, 
though he stressed that in some other countries, like Britain or the USA differentiation based 
on gender was not so clear (Sierosławski, 1998). Since the age of onset of schizophrenia in 
men is lower than in women, and drug use among young men is more prevalent, perhaps it 
may result in a fact that the population of patients with dual diagnosis is dominated by 
young men. Numerous studies show a predominance of males among people with dual 
diagnosis. In 1994 DeQuardo et al. evaluated the frequency of substance use among 
schizophrenic patients. In a population of addicts analysed by them, there were 48% of men 
and 20% of women. Maynard and Cox (1998) analyzed cross-sectionally a population of 
patients hospitalized in the U.S. due to various psychiatric disorders, and they found that 
among those with a dual diagnosis, the majority were males. Swartz et al. (2000) conducted 
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an epidemiological study including drug addicts in the U.S.. Among the people who 
developed a dual diagnosis, 70% were males, and most of them were in the age group of 30-
40 years. Salyers and Mueser (2001), studying a group of 404 patients with schizophrenia 
and schizoaffective disorder, found that in the subgroup that had used alcohol or drugs, 
women constituted a minority. Other sources of demographic and social analyses of patients 
with dual diagnosis indicate that the population of such patients consists mostly of men, 
who often do not work and are poorly educated (Drake & Mueser, 2000). Hambrecht and 
Hafner (2000) conducted research among a population of a billion participants from 
Germany, noting that among patients with the first episode of schizophrenia, male gender is 
a greater risk factor when it comes to cannabis abuse. Similar observations were made by 
Cantor-Graae in studies conducted in Sweden (2001) in which it was found that among 
patients with schizophrenia who use substances were far fewer women. French researchers 
analysed the demographics of patients with schizophrenia and the use of psychoactive 
substances. It turned out that in that group only 16.7% were women (Dervaux et al., 2003). 
Kavanagh et al. (2004) examining the incidence of substance use psychoactive drugs in 
patients with psychoses of various aetiologies noted a prevalence of males in the evaluated 
group.  
3.3 Level of education in the population of dual diagnosis patients 
As stated by Chouinard et al. (2003), the first episode of a serious mental illness usually 
appears at the beginning of adult life, and this is the age when people take important life 
decisions on, inter alia, the occupation. Suffering from psychiatric disorders is often 
associated with failure to achieve an adequate education, which may be a consequence of 
reduced social and economic status. In a Polish follow-up study conducted by Krupka-
Matuszczyk (1998) on a group of adolescents including 142 persons, it was observed that 
after the first hospitalisation 30% of young people did not continue education interrupted by 
illness. Patients with schizophrenia or bipolar disorder often appear to be poorer, positioned 
(economically and socially) in worse groups and regions. Achieving a lower educational 
level may be also the result of the use of psychoactive substances. Swaim et al. (1997) 
repeatedly observed a higher proportion of drug users in those who interrupted their 
education prematurely. In a study conducted in Australia it was found that weekly 
marijuana use in adolescents increases the risk of disruption of school before completing it 
(Lynskey et al., 2003). Oboth and Anthony (2000) found that among young Americans 
intravenous drug use causes frequent interruptions of education in high school. In further 
studies, Kavanagh et al., (2004) observed that having a lower educational attainment was 
correlated with the use of cannabis, but there was no such correlation with other drugs. In 
another study, devoted to patients with dual diagnosis, it was found that patients with 
schizophrenia addicted to alcohol or drugs achieve worse education in comparison to 
patients with schizophrenia without concomitant dependence (Potvin et al., 2003). Thus, the 
coexistence of addiction and a serious mental ilness may imply in a summation of the 
associated adverse factors affecting the level of education of the patients. 
4. Diagnostic problems 
Conducting epidemiological studies is complicated by the fact that the described problem is 
associated with a number of diagnostic questions. For example it is possible that some of the 
observed elevated rates of coexistence of bipolar disorder, or disorders of the bipolar 
www.intechopen.com
 
Comorbidity of a Serious Mental Illness with an Addiction to Psychoactive Substances 
 
433 
spectrum, such as cyclothymia, and addiction may be caused by the effects of consumption 
of psychoactive substances. This diagnostic error is less likely in patients with chronic, 
severe bipolar disorder or in those patients who clearly developed symptoms of bipolar 
disorder before they began using substances (Lewin & Hennesy, 2004). It is also sometimes 
difficult to make a differential diagnosis between schizophrenia and a drug related 
psychosis. Some helpful observations from the patient's behaviour may suggest the clinician 
the possibility of substance abuse by persons treated for various mental disorders. For 
example, patients can often ask the nurse for painkillers, and pharmaceuticals to treat 
different symptoms. This behaviour often distinguishes them from patients without 
substance abuse problems who are reluctant to take medications because of unpleasant 
experiences with side effect and because of an association with a stigma of a mental illness. 
Another clue suggesting addiction is a behaviour of the patient in the community of 
patients. Patients with a co-dependency often show a better functioning in a group of 
mentally ill persons. They show higher social skills and they are more adequate in the field 
of sexual behaviour. Patients with a co-dependence more often have a tendency to 
intimidate others, causing fear and respect among the staff and other patients (Solomon et 
al., 1993).  
5. Reasons for substance abuse among mentally ill people 
Why are disorders related to substance use so common in patients with serious mental 
illnesses? One of the attempts to explain this phenomenon is the self-medication hypothesis 
formulated by Khantzian (1985). In defining the self-medication, he draws attention to its 
two aspects. 1) There is a considerable degree of specificity in the choice of a psychoactive 
substance. 2) People use, abuse and become addicted to psychoactive substances because 
they reduce the feeling of psychological discomfort. This suggests that people with 
psychiatric disorders use specific substances (e.g. use heroin during a manic episode or 
stimulants during a depressive episode) in an attempt to prevent or "self-medicate" 
unpleasant symptoms, which ultimately leads to the re-use of these substances. The 
motivation to do it is often a result of subjective profits that the patients using them 
experience. The patients with schizophrenia use those substances in order to handle 
depression, to experience more profoundly different emotions, and to reduce the side-effects 
of the medication they are prescribed. The data show that illicit drugs are used to reduce 
depression (72%), and tension (64%) to increase pleasant emotions (62%), to enhance the 
ability to work and to learn (17%), to decrease the side-effects of the medication.(15%), to 
reduce hallucinations (11%) , suspicion (4%) and other symptoms (Dixon et al., 1991). The 
analysis of the causes of abuse of psychoactive substances by subjects with schizphrenia was 
made by a Canadian team, which attempted to balance gains and losses incurred by the 
patients reaching for psychoactive substances. In the patients' opinion marijuana and 
alcohol improved their social functioning. However besides the positive outcomes, the 
respondents emphasised that the reduction of depressive symptoms was often only their 
wish, because except for achieving such effects as relaxation, pleasure, being more active 
etc., the psychoactive substances may happent to be an uncontrolled and unexpected reason 
for an increase of depressive symptoms. In addition, in spite of achieving a feeling of 
increased satisfaction, the patients might experience an exacerbation of existing, or develop 
new positive symptoms of schizophrenia (Addington & Duchak, 1997). When evaluating the 
attractiveness of different substances for the patients suffering from schizophrenia it is very 
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important to distinguish between positive and negative symptoms of this disease. The 
positive symptoms usually implicate the abuse of tranquilisers, and the negative symptoms 
are most frequently a reason to develop a dependence than the positive symptoms. The 
incidence of negative symptoms is usually accompanied by increased suffering and the 
patient uses the substance to reduce it even if the relief is only transient. The study done in 
Australia (1995) was very important. 53 patients with comorbid diagnoses of schizophrenia 
and addiction to psychoactive substances were interviewed with the use of Brief Symptom 
Inventory and Schizophrenia/Substance Abuse Interview Schedule. Most of the patients 
reported that the use of substances was the reason for a development or exacerbation of 
their disease, 80% of them used drugs to handle their dysphoria and anxiety. The 
amphetamines caused their subjective improvement better than alcohol, however the choice 
of the substance depended mainly on what they could afford. Only cannabis exacerbated the 
positive symptoms and only amphetamines reduced negative symptoms (Baigent et al., 
1995). In other studies it was proven that different substances have influence on different 
problems related to the disease. For example alcohol, cannabis and cocaine decrease 
depression, cannabis and alcohol decrease the level of anxiety and cocaine increases it 
(Coben & Levy, 1998). The analysis of subjective experiences of the patients shows that 
handling the positive symptoms is the most difficult for them as alcohol has here only a 
limited influence, cannabis increases these symptoms and the effect of cocaine may be 
diverse depending on the individual patients.  
6. Impact of substance use on the course of psychiatric disorders 
The observations of the clinicians treating the dual diagnosis patients concerning the 
influence of the substance abuse on the course of the mental illness are inconsistent. 
According to some of them the patients suffering from schizophrenia abusing substances 
present less positive and negative symptoms, according to others the substance abuse highly 
deteriorates the course of the disease. Especially the stimulants like cocaine have a negative 
impact on the intensity of psychiatric symptoms. According to data from literature the only 
result of substance abuse is the increase of frequency of hospitalizations (LeDuc & 
Mittleman, 1995), and according to some other studies the impact on different symptoms 
may be diverse, e.g. alcohol causes an increase of positive symptoms, and it is also 
responsible for a higher frequency of suicidal attempts (Soyka, 1994). We have available 
data from the literature on the relationship between substance use and severity of clinical 
symptoms. Lysaker et al., (1994), found that patients with schizophrenia who use cocaine 
have less intense negative symptoms than patients, who do not use cocaine. Serper et al. 
(1995) found in schizophrenic patients with a concomitant use of cocaine lower scores of 
negative symptoms and higher scores of depression and anxiety. Salyers and Mueser (2001) 
examining patients with schizophrenia who used alcohol and drugs, observed lower 
intensity of negative symptoms than in patients without concomitant dependence. 
However, Soyka et al., (2001) found that the coexistence of addiction, causes only minor 
differences in the scores of positive and negative symptoms. Clearer differentiation of 
severity was related only hallucinations among patients with dual diagnosis. Norwegian 
authors who analysed the relationship between substance use and severity of PANSS scores 
in psychotic patients who used and who did not use psychoactive substances, did not 
observe differences in positive negative and general symptoms (Moller & Linaker, 2004). In 
contrast, Canadian researchers found that patients with dual diagnosis had a higher score in 
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PANSS than patients with schizophrenia alone (Margolese et al., 2003). Buhler et al (2002) 
examined populations of nonabused patients with schizophrenia and those addicted to 
alcohol and drugs (mainly cannabis). They found that patients with dual diagnosis 
experienced more severe positive symptoms. Similar results have also resulted in a study 
conducted by Green et al. (2002). In the work of Addington and Addington (1997) there was 
no overall significant difference in symptoms measured by PANSS scale between the group 
using and not using psychoactive substances. The exception was the subgroup of people 
who used cocaine, in which a higher severity of positive symptoms was observed. In a study 
conducted by Pencer and Addington (2003) analysing the cognitive functions in patients 
with first episode of psychosis, using psychoactive substances, an assessment of PANSS at 
the start, after one year and two years of observation was done. There was no difference in 
negative symptoms between the two groups, while those who did not use drugs had less 
severe positive symptoms. It must be remembered that the subjects throughout the period of 
observation have used psychoactive substances. Substance abuse can also have a negative 
impact on the course of the bipolar disorder. For example, it may be associated with earlier 
age of onset of the disorder and cause more difficulties in the therapy of the subtypes of the 
disease, such as rapid cycling, dysphoria and mixed states. Salloum et al. (2002) conducted a 
study covering 256 patients with acute manic episode, done in a municipal psychiatric ward, 
in which it was found that patients with severe symptoms of disease, abusing alcohol 
presented a significantly higher lability of mood, impulsivity and increased incidence of 
aggressive behaviour than patients with an acute manic episode without accompanying 
alcohol abuse. Furthermore, the coexistence of bipolar disorder and substance abuse is 
associated with an increased number of psychiatric hospitalisations and it is more difficult 
to achieve remission of acute manic episodes.  
7. Treatment strategies for patients with dual diagnosis 
These observations lead to a conlusion that a specific approach for the treatment of 
comorbid mental ilness and disturbances associated with the use of psychoactive substances 
is necessary. Currently, clinicians must often rely on their own observations rather than on 
empirical data to determine which therapies are best for this group of patients.  
7.1 Pharmacological treatment  
In schizophrenic patients with comorbid substance abuse the treatment with second-
generation antipsychotics may have beneficial effects on their symptoms. There are reports 
in the literature, which indicate the ability of these drugs to reduce other symptoms of the 
disease, as well as reducing the amount of drug used by patients treated with them.  
In the studies of subjects with schizophrenia and schizoaffective disorder, previously 
diagnosed as drug resistant, a subgroup of patients with dual diagnosis was selected. When 
they were switch on clozapine from classical neuroleptics in within six months, the authors 
noted that patients with a coexistence and without a coexistence of drug dependence 
responsed equally to the treatment (Buckley et al., 1994). Similar observations were made 
Volavka (1999), who noted that during a 6-month treatment with clozapine it could not be 
determined whether the difference in the treatment response between patients with 
schizophrenia and schizoaffective disorder depends on the fact if they use or do not use 
psychoactive substances. In turn, Zimmet et al (2000) found that over 85% of patients who 
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used psychoactive substances during their treatment with clozapine reduced the quanities 
of abused psychoactive substances. To similar conclusions also led the studies by Green et 
al., (2002) and also by Drake et al., (2000) in relation to patients who use alcohol, as well as 
research of Buckley et al. (1998) embracing patients with dual diagnosis abusing alcohol, 
cigarettes and cocaine. As it turned out, the classical neuroleptic treatment did not reduce 
the amount of abused substances. Probably the positive effects of clozapine treatment is due 
to the fact that it acts on mesocortical and mesolimbic dopaminergic neurons that are 
associated the reward system (Green et al., 1999). According to Noordsy et al., (2003) in 
patients with schizophrenia the reward system does not function properly, which increases 
the susceptibility to substance use. This may also underly the poorer tolerability of 
conventional antipsychotics in patients with dual diagnosis and the effectiveness of 
clozapine and, to a lesser extent, of other atypical antipsychotics in the treatment of this 
group of patients. According to Stip et al., (2003) and Weisman (2003) in the treatment of 
patients with dual diagnosis the most promising results were obtained with clozapine, and 
slightly worse results with olanzapine and quetiapine. Other studies have shown a 
reduction in the frequency of alcohol use after the change of treatment from classical 
neuroleptics to risperidone (Huang, 1996).  
As for the effect of various drugs used to treat bipolar disorder, a summary is made here 
Maremmani et al (2010). According to them, for example, carbamazepine is beneficial in 
preventing relapse in abusers of cocaine and has a positive effect on discomfort associated 
with fluctuations in mood, but it has no effect on the behaviour directed to obtain the 
substance. Selective response to lithium is achieved in alcoholics with a coexisting 
depression. Oxcarbazepine has a good effect of aggressive patients, while valproic acid 
generally is considered the drug effective in patients with coexisting bipolar disorder and 
addiction, but also in people with anxiety disorders and the accompanying dependence on 
psychoactive substances. The authors of that study conclude that some of these medicines 
are safe and effective agents that can be used in the treatment of addicted persons with 
mood disorders. 
7.2 Psychotherapy and rehabilitation 
Due to the above-described specific problems associated with diagnosing and treatiment of 
patients with dual diagnosis, specific treatment programs should be developed for them, 
which combine elements of both psychiatric treatment and addiction therapy. 
Understanding the causes of the problems described above is necessary for an effective 
prevention of drug abuse by people with mental illnesses. An example of therapeutic 
program for dual diagnosis patients with comorbid addiction to substances, with which the 
authors have a possibility to co-operate, is the Therapeutic Community “Famila” in Gliwice, 
Poland, which was founded by May-Majewski in the 80-ties. A comprehensive model of 
treating patients with dual diagnosis, offered by the Center for Addiction Treatment 
"Familia" allows them to move freely between the settings of two therapeutic models. The 
program is stationary, conducted in three separate buildings. They have registered 100 beds. 
The whole program employs three psychiatrists, 6 psychologists and 8 specialists in 
addiction therapy and nurses. The therapy takes place in a therapeutic community in which 
the average age is 23 years and in various small groups depending on the current needs of 
the patient. The treatment of the patient in the psychiatric ward usually follows a complex 
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diagnostic process. Depending on the patient's current condition, which for example may be 
acute or chronic, the patient may continue his or her treatment in a therapeutic community. 
The most important rules of the program are: 1) authority, 2) clear rules and principles. The 
fulfillment of these conditions is essential in building a therapeutic offer for the patients 
with an addiction to psychoactive substances and psychiatric disorders. These standards 
apply in therapeutic communities, where adherence to rules and principles is possible 
through the common responsibilty of all members of this community, both therapists and 
the patients. The most important factor in a succeful therapy are: receiving feedback from 
others, allowing to express emotions, a sense of belonging to a group, giving feedback to 
others, discovering that others have similar problems, receiving support from others, giving 
support to others, receiving tips and ideas from others. The participant of a therapeutic 
program is expected to make a gradual transition from the periphery of the therapeutic 
communitiy to a position, when he or she takes over certain responsibilities (May-Majewski, 
2002). Training of social skills is also a very important part of rehabilitation of patients with 
dual diagnosis. It includes skills such as: communication, interpersonal problem solving, 
active participation in their pharmacotherapy, learning to take care of their own health 
(Sawicka, 2001). A very important element that should be included in these programs is also 
a cognitive skills training, because, according to the the literature, patients participating in 
cognitive skills training significantly improve their performance on neuropsychological 
tests, they increase their insight. Keshavan and Hogarty (1999) developed the concept of 
"social cognition", which is associated with the term "emotional intelligence". The so-called 
"social cognition" is the central element of pathophysiology of certainn mental disorders like 
schizophrenia. People predisposed to the development of schizophrenia may use immature 
(concrete as opposed to abstract) styles which are inadequate for the more complex and 
abstract cognitive requirements specific to adults. In this way, they do not understand the 
essence of the subtleties and nuances of social interaction (Lewis, 2004). It appears that 
cognitive impairment is associated with various aspects of social functioning and problems 
in vocational activities. Data from literature suggest that they are particularly important for 
social functioning, quality of life, social skills, ability to benefit from learning new skills 
(Tamminga, 1998). 
8. Conclusion 
Understanding the causes of the problem described above is necessary for effective 
prevention of substance abuse by people with mental health problems. The results of 
available studies suggest that these patients have an increased risk of a relapse of both the 
disease and the addiction to substances. In addition to the symptoms they experience, one of 
the very important problem in the lives of these patients is their difficulty in social 
functioning. Effective therapy for these individuals should include: making it possible to 
create a protective environment, assisting these people in makin important changes in their 
lives, such as finding a good job, friends abstaining from drugs and alcohol, a group of 
people who can help the patient to find sense their lives. Patients directed to a therapeutic 
program must be motivated to make changes in their current life. This decision must be 
conscious and and be a free choice of the patient. It is also necessary to apply specific, 
individualied forms of therapy of, mental disorders and those associated with subsatnce 
abuse.  
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